Board of directors and executive management


DexTech’s organisation is optimised according to the company’s current needs, and consists of one (1) full time employee plus a network of experienced advisers and consultants providing all the functions necessary to fulfil DexTech’s development plans. This setup minimises fixed overheads and makes the company far more robust than the norm. The plan calls for the organisation to be kept at the current level for the foreseeable future. Gösta Lundgren, CFO, is a shareholder in DexTech and play an active role in DexTech’s business activities as consultant. DexTech’s strategy is to continue to minimise administrative overheads until the company is earning external revenues.

How the board works

Board of directors and executive management

Andreas Segerros – Chairman

Andreas Segerros has long and solid experience with executive positions in the international pharmaceutical industry, in Europe, the USA and Japan.

Anders R Holmberg – founder, CEO and board member

Anders R Holmberg is the founder, board member and CEO of DexTech. Holmberg holds a doctorate in medicine from Uppsala University, and is a qualified chemical engineer. He specialises in chemical glycosylation, with over 30 years of experience including process development. He was employed at Pharmacia Corporation between 1978-1997. Holmberg was also Director of Development at MAP Medical Applied Products AB/Oy, 1999-2003, and CEO of MAP AB, 2001-2003. Anders R Holmberg has had around 50 scientific articles published.

Sten Nilsson – founder and board member

Sten Nilsson, born 1948, founder and board member Doctor of Medicine, PhD, professor in oncology. Nilsson is an internationally-acknowledged authority within urological oncology, especially prostate cancer. After over 30 years of clinical experience, he has access to an extensive international network. Nilsson is employed as professor and consultant at the Radiumhemmet hospital. Through his profession, Sten Nilsson has daily contact with the clinical reality of prostate patients. He also has extensive experience of clinical studies with new medications, as he has been involved in the design and execution of the Algeta/Bayer phase I, II and III studies for Alpharadin/Xofigo. Sten Nilsson has published around 200 scientific articles.

Svante Wadman – board member

Per Asplund – board member

Rolf Eriksson – board member

Gösta Lundgren – CFO, Head of Investor Relations